IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.

Slides:

Advertisements

Similar presentations

Memorial Sloan-Kettering Cancer Center

Advertisements

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.

THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.

The PRIAS Study In Australia One Institution’s Experience Introduction PRIAS (Prostate cancer Research International: Active Surveillance – NTR1718) is.

Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.

Role of MRI and MRSI in The Management of Prostate Cancer Karim Touijer, MD.

Steven Joniau Filip Ameye

PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K.

RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

How and when to use nomograms for counseling patients with prostate cancer ? By the BAU Working Group of Urology.

Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib Davis KL et al. Proc ASH 2014;Abstract.

PCa Screening New Areas of Research Francesco Montorsi Milan.

DISCUSSION AND CONCLUSION Alberto Briganti Urological Research Institute Vita Salute San Raffaele University Dept. of Urology, Milan, Italy.

INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,

on behalf of the ACOSOG Z4032 Investigators

Lymphadenectomy in the surgical treatment of prostate cancer - does it influence survival? Oliver Hakenberg Urologische Klinik und Poliklinik Universitätsklinikum.

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.

A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.

Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

LOCAL TREATMENT OF OLIGOMETASTATIC DISEASE IN PROSTATE CANCER: LYMPHADENECTOMY Alberto Briganti, MD, fEBU Department of Urology Chair, Prostate Cancer.

Fig. 1: Regional abdominal lymph node dissection during 2-field LND. Fig. 2: full mobilisation of spleen and pancreatic tail to allow complete LND of.

Klinikum rechts der Isar, Technische Universität München

#4826 Cancer/testis antigen expression pattern is a potential biomarker for prostate cancer aggressiveness Luciane T. Kagohara1, Prakash Kulkarni1, Takumi.

Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series

Volume 61, Issue 3, Pages (March 2012)

Prognostic significance of tumor subtypes in male breast cancer:

Surgical Treatment in Locally Advanced Prostate Cancer

Bladder Cancer and Prostatic Cancer

1 LINFOADENECTOMIA Alessandro Volpe Università del Piemonte Orientale

J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI

Radical Prostatectomy in pN+ Prostate Cancer

Post Op Positive Apex Margins Case 3: Prostate_3

New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.

RELAZIONE TRA “STAGE MIGRATION” E

Post Op Positive Seminal Vesicle Case 4: Prostate_4

Prostate Cancer: Highlights from 2006

Development and internal-external validation of a multivariable prediction model for pre-operative assessment of positive lymph nodes during robot assisted.

Volume 61, Issue 5, Pages (May 2012)

Volume 51, Issue 6, Pages (June 2007)

ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE

Apollo Gleneagles Hospitals,

Volume 63, Issue 6, Pages (June 2013)

Volume 67, Issue 2, Pages (February 2015)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 73, Issue 4, Pages (April 2018)

Current Guidelines in the treatment of Prostate Cancer: what is most appropriate for Nigerian patients? Dr Emmanuel Ajibola Jeje BSc. M. B. Ch.B; FMCS;

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Active Surveillance for Low Risk Prostate Cancer

Patients who have received chemotherapy (n=60)

Disease-specific survival

Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.

Published online September 20, 2017 by JAMA Surgery

HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. , JOSEPH E

Volume 50, Issue 5, Pages (November 2006)

Volume 54, Issue 2, Pages (August 2008)

Management of Prostate Cancer: Global Strategies

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Presentation transcript:

IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION Fossati N, Abdollah F, Larcher A, Montorsi F, Briganti A, Guazzoni G Urological Research Institute, Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy # 26

Introduction  Previous studies have shown a decrease in the prevalence of prostate cancer (PCa) lymph node metastases in the recent years.  However, these data might be biased by decreased rates and extents of pelvic lymph node dissections (PLND).  We therefore assessed the evolution of rates and tumor characteristics of men with node positive disease at radical prostatectomy (RP) and extended PLND (ePLND) at a single tertiary referral center over the last two decades.

 5274 PCa patients treated with open RP and ePLND ( ).  All patients received an anatomically defined ePLND. Materials and Methods

o Year-per-year trends of lymph node invasion (LNI) rates and clinical and pathological characteristics were examined. o The same analyses were repeated according to cancer characteristics, after stratification of patients into: - Low risk: PSA<10 ng/ml, clinical stage T1 and BxGS ≤ 6 - High risk: PSA>20 ng/ml or clinical stage T3 or BxGS Intermediate risk: all the remaining patients o Univariable and multivariable logistic regression analyses addressed predictors of LNI, including year of surgery as predictor as well as patient and tumor characteristics. Materials and Methods

Results Overall 5274 (100%) (8.0%) (18.7%) (37.9%) (35.4%) p value NCCN classification Low-risk Intermediate-risk High-risk 1473 (27.9) 2298 (43.6) 1503 (28.5) 54 (12.9) 171 (40.7) 195 (46.4) 240 (24.4) 324 (32.9) 420 (42.7) 604 (30.2) 944 (47.2) 453 (22.6) 575 (30.8) 859 (46.0) 435 (23.3) <0.001 Pathological stage T2 T3a T3b T (65.8) 809 (15.3) 888 (16.8) 108 (2.0) 227 (54.0) 63 (15.0) 109 (26.0) 21 (5.0) 617 (62.7) 135 (13.7) 188 (19.1) 44 (4.5) 1395 (69.7) 280 (14.0) 308 (15.4) 18 (0.9) 1230 (65.8) 331 (17.7) 283 (15.1) 25 (1.3) <0.001 Pathological GS ≤ ≥ (42.6) 1556 (29.5) 681 (12.9) 790 (15.0) 261 (62.1) 65 (15.5) 25 (6.0) 69 (16.4) 592 (60.2) 180 (18.3) 95 (9.7) 117 (11.9) 788 (39.4) 664 (33.2) 275 (13.7) 274 (13.7) 606 (32.4) 647 (34.6) 286 (15.3) 330 (17.7) <0.001 N° of LN removed Mean Median Range <0.001 Lymph node invasion pN0 pN (86.2) 730 (13.8) 334 (79.5) 86 (20.5) 838 (85.2) 146 (14.8) 1755 (87.7) 246 (12.3) 1617 (86.5) 252 (13.5) <0.001 Descriptive characteristics of 5274 patients treated with RP and ePLND, classified according to year of surgery.

Results Year-per-year trend analysis of lymph node invasion rates in the overall patient population. Year-per-year trend analysis of lymph node invasion rates, according to NCCN risk groups.

Results Univariable analysisMultivariable analysis OR (95% CI)p valueOR (95% CI)p value Year of surgery category (Ref.) 0.68 ( ) 0.54 ( ) 0.61 ( ) --- < < (Ref.) 0.83 ( ) 0.76 ( ) 0.68 ( ) PSA level (ng/ml)1.04 ( )< ( )<.001 Pathological stage T2 T3a T3b T (Ref.) 8.58 ( ) ( ) ( ) --- < (Ref.) 5.32 ( ) ( ) ( ) --- <.001 Pathological Gleason score ≤ ≥ (Ref.) 2.55 ( ) 6.71 ( ) ( ) --- < (Ref.) 1.62 ( ) 2.6 ( ) 4.69 ( ) <.001 N° of LN removed1.05 ( )< ( )<.001 Univariable and multivariable logistic regression analyses predicting lymph node invasion (LNI) in 5274 patients treated with RP and ePLND.

Results Univariable analysisMultivariable analysis OR (95% CI)p valueOR (95% CI)p value Year of surgery category (Ref.) 0.68 ( ) 0.54 ( ) 0.61 ( ) --- < < (Ref.) 0.83 ( ) 0.76 ( ) 0.68 ( ) PSA level (ng/ml)1.04 ( )< ( )<.001 Pathological stage T2 T3a T3b T (Ref.) 8.58 ( ) ( ) ( ) --- < (Ref.) 5.32 ( ) ( ) ( ) --- <.001 Pathological Gleason score ≤ ≥ (Ref.) 2.55 ( ) 6.71 ( ) ( ) --- < (Ref.) 1.62 ( ) 2.6 ( ) 4.69 ( ) <.001 N° of LN removed1.05 ( )< ( )<.001 Univariable and multivariable logistic regression analyses predicting lymph node invasion (LNI) in 5274 patients treated with RP and ePLND.

Conclusions A significant reduction in LNI rates over time was observed in our large cohort of patients homogeneoulsy treated with anatomically defined ePLND over two decades. However, contemporary intermediate and high risk patients still harbor a significant LNI risk if treated with ePLND. In consequence, stage migration does not justify omitting or limiting the extent of PLND in intermediate and high risk PCa patients.